Mirtimash

Quick links to important sections

Mirtimash

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirtimash

Mirtimash is a prescription-only psychotropic drug containing the active substance Mirtazapine. It is a single-ingredient product and a synthetic compound primarily used to support emotional balance in adults managing major depressive disorder.

Property Description
Active ingredient Mirtazapine
Form Oral tablet (Film-coated and Orally Disintegrating Tablets (ODTs))
Pharmacological class Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
Common use Management of Major Depressive Disorder (MDD)
Origin Synthetic compound

Mirtazapine's Distinct Pharmacological Profile

Mirtazapine is structurally classified as a Tetracyclic Antidepressant (TeCA), but it is functionally known as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). In this capacity, Mirtazapine enhances the release of the key brain messengers noradrenaline and serotonin. The NaSSA action is clinically recognized for balancing brain chemistry in a manner distinct from classes like Selective Serotonin Reuptake Inhibitors (SSRIs).

The unique profile of Mirtazapine is further differentiated by its ability to act as a potent antagonist of histamine (H1) receptors. This specific action is believed to be the reason Mirtazapine is frequently chosen for individuals with depression complicated by sleep disturbances or poor appetite.

Available Forms and Composition Identity

Mirtazapine is designed for oral administration and is supplied as either a standard film-coated tablet or an Orally Disintegrating Tablet (ODT). The ODT form offers a convenient mode of administration as it dissolves quickly on the tongue. The basic composition of the drug consists solely of the active ingredient Mirtazapine, combined with the necessary solid pharmaceutical excipients (inert components) required for tablet production.

Regulatory References

  1. StatPearls, NIH
  2. DailyMed, NIH

What side effects are possible with Mirtimash?

The official safety profile for Mirtazapine (Mirtimash) describes potential adverse reactions by frequency and affected body system, strictly based on government regulatory documentation.

Adverse Reaction Classification

Adverse reactions that are classified as Very Common (occurring in 10% or more of users) typically relate to the Central Nervous System and Metabolism, and include somnolence or sedation, increased appetite, and weight gain. Common effects (1% to 10% of users) may involve the Nervous System (dizziness, tremor), Gastrointestinal system (dry mouth, constipation), and Vascular system (orthostatic hypotension, peripheral edema).

Serious Adverse Reactions and Key Warnings

Regulatory documents highlight rare but medically critical adverse reactions. The most serious include Agranulocytosis and other forms of Bone Marrow Depression, which typically appear early in treatment. The labeling also includes a Boxed Warning regarding the increased risk of Suicidal Thoughts and Behaviors in younger adults, adolescents, and children, particularly at treatment initiation or following dose adjustments. Other documented serious reactions include Serotonin Syndrome, Severe Cutaneous Reactions, and QT prolongation.

Safety Considerations for Specific Populations

Safety notes specify that Older Adults may be at greater risk for certain side effects, such as Hyponatremia and CNS effects like confusion or over-sedation. For individuals with Renal or Hepatic Impairment, the drug's clearance is reduced, which can lead to increased exposure and may require monitoring. The medication is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of a severe reaction.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile of Mirtazapine (Mirtimash) based on documented clinical manifestations and mandated emergency actions. Overdose is primarily associated with central nervous system (CNS) effects, which include drowsiness, confusion, disorientation, and impaired memory. Cardiovascular effects such as tachycardia (fast heart rate) and a slight prolongation of the QTc interval have also been formally documented.


Severe Outcomes and Emergency Action

Serotonin Syndrome, a potentially life-threatening condition involving symptoms like agitation, hallucinations, muscle rigidity, and seizures, is listed as a serious outcome that may occur. The risk of toxicity may be increased with co-ingestion alongside other CNS depressants, including alcohol.

Urgent medical care must be sought immediately following a suspected overdose. Regulatory guidance mandates that emergency services must be called if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Furthermore, the Poison Control Helpline should be contacted immediately.

No specific antidote is known to reverse the effects. Management is limited to symptomatic and supportive treatment, with measures such as gastric lavage or activated charcoal potentially being considered.

Therapeutic Uses of Mirtimash

What Mirtimash Treats: Main Uses and Benefits

Mirtimash is commonly used across conditions characterized by periods of heightened symptoms associated with Major Depressive Disorder (MDD). It is generally considered relevant when supportive symptom management is appropriate for conditions associated with moderate-to-severe illness.

The medication is primarily applied in addressing symptom clusters that may become intense or disruptive, including core low mood, persistent sadness, anhedonia (loss of pleasure), sleep disturbances, and clinical poor appetite. It is often used during phases when these symptoms become more noticeable, particularly in scenarios where patients experience significant nutritional or sleep-related strain. Its application is intended to provide supportive relief that helps patients cope more steadily with symptom fluctuations.

“This medication is considered relevant in clinical settings marked by increased patient discomfort, where comprehensive symptomatic support is needed.”


Quick Fact: Managing Sleep and Appetite Symptoms

The medication plays a role in managing symptoms related to poor appetite and insomnia alongside core mood management. This function may contribute to improved comfort during symptomatic periods, supporting the patient during difficult episodes and general physical well-being.

Regulatory References

  1. Mirtazapine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Mirtimash (mirtazapine) is an antidepressant prescribed for the treatment of Major Depressive Disorder (MDD).

Who Can Use Mirtimash?

Mirtimash is typically prescribed for adults diagnosed with MDD. Patients should be closely monitored, especially early in treatment or after dose changes, due to the potential for worsening depression or the emergence of suicidal thoughts and behaviors. The decision to use Mirtimash requires a careful evaluation of the benefits and risks by a healthcare provider, especially in individuals with a history of heart conditions, seizures, liver or kidney impairment, or bipolar disorder.

Who Cannot Use Mirtimash (Contraindications)?

Mirtimash is strictly contraindicated for use in certain patient groups to prevent serious, potentially life-threatening reactions. It must not be used by:

  • Individuals with a known allergy or hypersensitivity to mirtazapine or any component of the formulation.
  • Patients who are taking, or have taken within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI), including linezolid and intravenous methylene blue, due to the high risk of developing Serotonin Syndrome.
  • It is generally not recommended for children and adolescents under the age of 18, as studies show an increased risk of suicide-related thoughts and behavior in this age group when taking antidepressants.

Patients with untreated narrow-angle glaucoma or a high risk of QT prolongation (a heart rhythm disorder) also require careful consideration, and the drug may be contraindicated in certain cases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug and drug-substance interactions for Mirtimash (Mirtazapine), categorized by their mechanistic basis and clinical constraint.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Regulatory Constraint and Mechanism
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. A mandatory 14-day washout period is required when switching between Mirtimash and an MAOI.
Strong CYP3A4 Inducers (e.g., Carbamazepine) Requires close monitoring and potential increase in Mirtimash dosage due to reduced Mirtimash plasma concentrations.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Requires close monitoring and potential decrease in Mirtimash dosage due to increased Mirtimash plasma concentrations.
Other Serotonergic Drugs (e.g., SSRIs, Triptans) Requires close patient monitoring for the heightened risk of Serotonin Syndrome (Pharmacodynamic Effect).
CNS Depressants and Alcohol Use with caution due to additive CNS depression (Pharmacodynamic Effect).
Warfarin Requires monitoring of the International Normalized Ratio (INR) as Mirtimash may increase it.

Regulatory Summary

The interaction profile dictates a strict avoidance of MAOIs and mandates dosage adjustments when combined with strong CYP3A4 modulators due to enzyme-mediated exposure changes. Other clinically significant combinations require active patient monitoring to manage the risk of additive pharmacodynamic effects.

Mechanism of Action

How Mirtimash Works

Mirtimash operates through a multi-target mechanism within the central nervous system. Its primary action involves binding to and blocking presynaptic boldsymbolalpha2-Adrenergic Autoreceptors on nerve terminals. This antagonism removes an inhibitory feedback loop, leading to an increased synaptic availability of the neurotransmitters Norepinephrine and Serotonin.

Simultaneously, the molecule acts as an antagonist at several postsynaptic sites, notably Serotonin boldsymbol5- HT2 A and boldsymbol5- HT3 receptors. This blockade ensures that the enhanced Serotonin activity is preferentially directed toward the boldsymbol5- HT1 receptor family, resulting in a focused Serotonergic message and limiting associated downstream effects.

Additionally, the drug exhibits antagonism at the central Histamine boldsymbol H1 receptor. Blocking the H1 system, a major regulator of alertness, alters the central state of arousal, thereby modulating the physiological sleep-wake cycle.

Dosage and Administration Information

Official Instructions for Use (Mirtazapine)

The administration of this medicine is based on standard pharmacological guidance for mirtazapine, which is available in two main forms for oral intake: film-coated tablets and orally disintegrating tablets.

Dosing and Scheduling

The medicine is typically taken once daily, preferably in the evening prior to sleep. It may be taken with or without food.

Population Starting Dose Titration Maximum Labeled Dose
Adults 15 mg once daily Increases must not occur in less than 1 to 2 weeks intervals. 45 mg once daily
Geriatric Patients Lower starting dose (e.g., 7.5 mg/day) Close supervision is required for dose increases. 45 mg once daily

Administration Technique

  • Film-coated Tablets: These must be swallowed whole without chewing, with or without fluid. Scored tablets may be halved to achieve a lower dose.
  • Orally Disintegrating Tablets (ODT): The tablet must remain in the blister pack until immediately before use. With dry hands, place the whole tablet on the tongue, where it will rapidly disintegrate and can be swallowed with saliva; no water is needed.

Special Administration Rules

Missed Dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, the missed dose should be skipped to maintain the regular schedule; do not take two doses at once.

Special Populations: A dosage decrease may be needed for patients with moderate to severe hepatic (liver) or renal (kidney) impairment. The medicine is not approved for use in pediatric patients (under 18 years).

Course Duration: The drug should be gradually discontinued after the appropriate treatment period, which is often continued until the patient has been symptom-free for several months.

Recent Clinical Evidence

Research Focus and Primary Findings

Studies have focused on the drug's proposed action at nerve endings involving substance P. This mechanism forms the basis for the drug's study in managing pain signal transmission.

Studies have explored the drug's profile in individuals with chronic neuropathic pain. The evidence has primarily been gathered from numerous randomized controlled trials (RCTs).

In these RCTs, studies reported a difference in patient-reported pain scores over a 12-week period compared to placebo.


Combination Therapy Trials and Secondary Outcomes

Research evaluated the drug's co-administration with standard antidepressant medication. Studies examined whether the combination was associated with changes in daily function compared to monotherapy alone.

Research also explored whether this approach was associated with a reduction in pain interference with sleep. The primary outcomes measured in these trials included the duration and quality of sleep.


Study Conduct and Observed Events

Study participants received the drug under medical supervision, with dosage limits based on the study protocol. Some research explored the drug's association with relief during acute flare-ups.

Studies examined the drug's side-effect profile. Commonly observed events included fatigue, dry mouth, and mild dizziness. Research protocols utilized dose titration, starting with a low dose and increasing slowly to examine the incidence of initial side effects.

Research included individuals with mild hepatic impairment. Study protocols specified the exclusion of individuals with severe liver disease in certain trials. No formal studies were provided regarding use during pregnancy or breastfeeding, and this remains an area for further research.

Frequently Asked Questions (FAQ)

Common questions about Mirtimash (FAQ)

Q: Is Mirtimash considered an antidepressant or an anti-anxiety medicine?

A: Official product information states that Mirtimash is an antidepressant primarily indicated for Major Depressive Disorder (MDD). However, the official label notes that Mirtazapine demonstrated superior efficacy over placebo on the anxiety/somatization factor of the Hamilton Depression Rating Scale (HDRS).

Q: Can Mirtimash help increase appetite and lead to weight gain?

A: Yes, increased appetite and weight gain are listed as very common adverse reactions in regulatory documents. This means they are frequent and expected effects of the medication that have been reported across clinical trials.

Q: How long does it typically take for Mirtimash to start working for depression?

A: While the exact time frame varies for each person, the clinical effects of Mirtimash (Mirtazapine) may sometimes be observed as early as one week after treatment begins. It often takes a few weeks to feel the full effects, and steady-state drug levels are usually achieved within a few days of starting treatment.

Q: Is it normal to feel extra sleepy or drowsy when first starting Mirtimash?

A: Yes, feeling somnolent (sleepy) or sedated is a very common side effect, meaning it occurs in 10% or more of users. This effect is often related to how the medicine acts on the brain's histamine system and is a frequent and expected experience when first starting treatment.

Q: What should I do if I experience dizziness after taking Mirtimash?

A: Dizziness is a common side effect that may impair your ability to think and move. If dizziness occurs, regulatory warnings advise caution when performing tasks that require mental alertness, such as driving or operating complex machinery.

Q: Are there any specific supplements or herbal remedies to avoid while on Mirtimash?

A: Official information cautions against combining Mirtimash with the herbal remedy St. John's Wort. This is because the combination may increase the risk of a serious condition called Serotonin Syndrome. It is important to ensure all concomitant herbal remedies and supplements are disclosed to a healthcare provider.

Q: Can Mirtimash be taken if a person has a history of seizures?

A: Mirtimash should be used with caution in patients who have a history of seizures, as seizures have been reported in some users. Close supervision by a healthcare provider is necessary, and the medication may be discontinued if a patient develops seizures.

Q: Will taking Mirtimash affect my ability to drive or operate machinery?

A: Yes, because common side effects include sedation and dizziness, Mirtimash may impair your judgment and motor skills. Official warnings indicate that caution is advised when performing tasks that require mental alertness, such as driving or operating heavy machinery.

Q: What kind of symptoms are associated with stopping Mirtimash?

A: When Mirtimash is stopped abruptly, a person may experience a discontinuation syndrome with symptoms such as dizziness, anxiety, nausea, abnormal dreams, agitation, or tingling sensations. Regulatory documents note that the dose should be gradually reduced, not stopped abruptly, to manage the risk of these symptoms.

Q: Does Mirtimash affect blood pressure or cholesterol levels?

A: Official information indicates that Mirtimash can cause a drop in blood pressure when moving from sitting or lying down to standing, known as orthostatic hypotension. Furthermore, elevated cholesterol and triglyceride levels have been reported as a possible adverse effect.

Q: Can Mirtimash be used just for anxiety without depression?

A: The only condition for which Mirtimash is officially approved is Major Depressive Disorder (MDD). Its use for anxiety alone is generally not included in the primary regulatory labeling.

Q: Is Mirtimash a type of SSRI, or is it different?

A: Mirtimash is not an SSRI (Selective Serotonin Reuptake Inhibitor); it has a different mechanism of action and is classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). Its action works by blocking certain receptors in the brain to enhance the release of serotonin and norepinephrine.

Q: What is the difference between Mirtimash and other common antidepressants like Zoloft or Prozac?

A: Mirtimash belongs to a different drug class (NaSSA) than SSRIs like Zoloft (sertraline) or Prozac (fluoxetine). Its unique mechanism enhances norepinephrine and serotonin and is associated with a different side effect profile, including a potentially lower incidence of sexual dysfunction.

Q: Why does Mirtimash often cause an increase in appetite and weight gain?

A: According to research on the drug’s mechanism, the reason for increased appetite and weight gain is believed to be its potent blocking of the central histamine H1 receptors. This action is also linked to its sedative properties.

Q: Is dry mouth a common and persistent side effect of Mirtimash?

A: Dry mouth is listed as a common side effect, meaning it is reported in between 1% and 10% of users. Official regulatory documents do not generally specify how long this symptom persists or whether it is chronic.

Q: Can Mirtimash cause abnormal dreams or nightmares?

A: Yes, abnormal dreams are listed in the official safety information as a possible adverse reaction associated with Mirtimash use.

Q: Is Mirtimash a high-risk medication during pregnancy?

A: Use during pregnancy is only advised when the potential benefit is considered to outweigh the potential risks to the fetus. The effects on human pregnancy are not fully established.

Q: Does Mirtimash affect sex drive or sexual function?

A: Clinical data suggests that Mirtimash is associated with a low incidence of sexual dysfunction compared to other classes of antidepressants like SSRIs. This may make it a potential alternative for patients concerned about this type of side effect.

Q: What are the signs of a rare but serious side effect like low white blood cell count (agranulocytosis)?

A: Agranulocytosis (a serious drop in white blood cells) is a rare but critical side effect. If symptoms such as a fever, chills, sore throat, or other flu-like signs develop, prompt consultation with a healthcare professional is recommended.

Q: Is Mirtimash known to cause low sodium levels (hyponatremia)?

A: Yes, hyponatremia (abnormally low sodium in the blood) has been reported with the use of Mirtimash. Older adults may be at an increased risk of developing this side effect.

Q: Is there a risk of developing mania when taking Mirtimash if I have an underlying mood disorder?

A: Yes, Mirtimash may activate mania or hypomania in some patients, particularly in those with a history of bipolar disorder. For this reason, it is generally used with caution in these individuals.

Q: Does Mirtimash cause constipation for most people?

A: Constipation is listed in regulatory documents as a common side effect, meaning it is reported by 1% to 10% of users. It is not classified as a 'very common' effect, which would affect 10% or more of people.

Q: Is the feeling of being 'wired' or agitated after starting Mirtimash a side effect?

A: Official information lists agitation as a possible adverse reaction. It is sometimes reported during treatment and may also occur as a symptom if the drug is suddenly stopped.

How should Mirtimash be stored and disposed of?

Storage Requirements

Mirtimash must be stored at controlled room temperature, typically 20 C to 25 C, with excursions permitted up to 30 C. The medicine must be kept in its tightly closed, original container and protected from light and moisture. It is essential to keep the medicine from freezing and from excessive heat.

Handling and Stability

For the orally disintegrating tablet form, the medicine should remain in its blister pack until the moment of administration. Once the blister is opened, the tablet must be used immediately and cannot be stored.

Disposal of Unused Medicine

Always keep Mirtimash and all medicines out of the sight and reach of children and pets. Any unused or expired medicine must be disposed of according to national and local requirements. If a drug take-back program is unavailable, government guidelines recommend mixing the medicine with an undesirable substance (such as used coffee grounds or cat litter) before sealing it in a bag and placing it in the household trash. Do not flush the medicine down a toilet or pour it down a sink unless specifically instructed by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirtimash found in:

A-Z Index: